Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639)

Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639): A Powerful Tool for Immunotherapy Research

Introduction

The Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) is a highly specific and potent tool for immunotherapy research. This antibody targets the CD134/TNFRSF4/OX40 protein, a member of the tumor necrosis factor receptor superfamily, which plays a crucial role in regulating immune responses.

Biological Function

CD134/TNFRSF4/OX40 is a co-stimulatory molecule expressed on activated T cells and is involved in the activation, proliferation, and survival of T cells. It also promotes the differentiation of T cells into effector and memory T cells, making it a key player in the adaptive immune response. The Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) specifically binds to this protein, blocking its interaction with its ligand and inhibiting downstream signaling pathways.

Main Applications

The Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) has a wide range of applications in immunotherapy research. It can be used to study the role of CD134/TNFRSF4/OX40 in various immune-mediated diseases, such as cancer, autoimmune disorders, and infectious diseases. It can also be used to investigate the efficacy of CD134/TNFRSF4/OX40 as a potential target for immunotherapy.

Experimental Use Cases

This antibody has been extensively used in pre-clinical studies to evaluate its potential as a therapeutic agent. In a recent study, the Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) was found to enhance the anti-tumor immune response and inhibit tumor growth in a mouse model of melanoma. Another study showed that this antibody can enhance the efficacy of anti-PD-1 immunotherapy in a mouse model of lung cancer.

The Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) is a powerful tool for immunotherapy research, targeting the CD134/TNFRSF4/OX40 protein and inhibiting its signaling pathways. It has a wide range of applications and has shown promising results in pre-clinical studies.

Conclusion

In summary, the Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) is a highly specific and potent tool for studying the role of CD134/TNFRSF4/OX40 in immune-mediated diseases and evaluating its potential as a therapeutic target. Its use in pre-clinical studies has shown promising results, making it a valuable addition to any immunotherapy research toolkit.